Accession Number : AD1049892


Title :   Novel Therapy for Bone Regeneration in Large Segmental Defects


Descriptive Note : Technical Report,30 Sep 2013,29 Sep 2017


Corporate Author : Indiana University Indianapolis United States


Personal Author(s) : Kacena, Melissa ; McKinley,Todd ; Chu,Tien-Min


Full Text : http://www.dtic.mil/dtic/tr/fulltext/u2/1049892.pdf


Report Date : 01 Dec 2017


Pagination or Media Count : 64


Abstract : The purpose of this study is to test the efficacy of thrombopoietin (TPO) to heal a segmental bone defect (SBD) in a large animal model, the minipig. The scope of the research comprises the following specific aims (i) to determine the union rate of tibial midshaft defects in minipigs treated with BMP-2, TPO, or saline control; and (ii) to evaluate the safety and side effects of treating tibial midshaft defects in minipigs treated with BMP-2, TPO, or saline control. Over the course of our study we completed surgeries on 51 minipigs. Three minipigs were used to develop our model. Of the others, 24 had a 25mm defect and were fixed with an IM nail, 12 had a 25mm defect and were fixed with a compression plate, and 12 had a 40mm defect and were also fixed with a compression plate. Perhaps the two most significant findings are: 1) we discovered that fixation type (IM nail vs. compression plates) impacts the size requirement for a critical size defect, and2) although the dose and timing may not yet be optimized, TPO can heal bone defects in pigs and is able to more rapidly allow for bone healing than observed in saline treated controls. Further, no toxic effects were observed, and although additional analyses remain to be completed, TPO and BMP-2 appear to work by different mechanisms to elicit bone healing.


Descriptors :   therapy , peptide growth factors , bone fractures , osteogenesis , orthopedic surgical procedures , proteins , osteoblasts , calcium compounds , regenerative medicine , bone regeneration , transplants , stem cells , PIGS


Subject Categories : Anatomy and Physiology


Distribution Statement : APPROVED FOR PUBLIC RELEASE